Treatment
HNC
LYMPH NODE METASTASIS
RT dose for patients with BC was 50 Gy/25 fractions delivered over 5 weeks. Most patients (88.2%) received 3-dimensional conformal radiation therapy (3D-CRT), and 6 patients (11.8%) received volumetric modulated arc radiation therapy (VMAT). To elevate skin dose, all patients were treated with 5 mm bolus over chest wall before 15 fractions of radiotherapy. For postoperative HNC patients, RT dose at 2 Gy/fraction was administrated once daily with five fraction per week up to total dose of 50-55 Gy. If radical radiotherapy was administrated, patients would receive up to a total dose of ≥ 66 Gy RT with cisplatin-based concurrent chemoradiotherapy (CCRT). Patients with high-risk factors of postoperation, such as positive margin and extracapsular spread in lymph node metastasis, received CCRT. The concurrent chemotherapy regimen was triweekly 80-100 mg/mFor the Sanyrene arm and control arm, patients were asked to start topical application of Sanyrene and control intervention cream respectively on the area of skin being irradiated at the onset of radiotherapy, twice a day up to 14 days post treatment. Sanyrene is a liquid dressing with characteristics of oily, colorless and fragrance of fennel. Control intervention is a white cream with fragrance. If moist desquamation occurred, these interventions would be stopped, then treating nurses applied epidermal growth factor solution and Silver Sulphadiazine impregnated Hydrocolloid Dressing 10 cm×12 cm until the wound healed.